Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 7/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31342590 | 0.89 | FFAR4 (0.39) | HRH4GRM5CNR1DRD4GRM2 | |
| SCHEMBL24753633 | 0.85 | HTR1A (0.46) | FFAR4HTR1A | |
| SCHEMBL31342747 | 0.85 | CNR1 (0.37) | HRH4CNR1FFAR4 | |
| SCHEMBL31342671 | 0.85 | CNR1 (0.37) | HRH4CNR1FFAR4 | |
| SCHEMBL29013165 | 0.85 | GRM5 (0.48) | GRM5FFAR4 | |
| SCHEMBL30796430 | 0.85 | GRM5 (0.41) | GRM5FFAR4 | |
| SCHEMBL27452094 | 0.85 | GRM5 (0.41) | GRM5FFAR4 | |
| SCHEMBL30883480 | 0.84 | HTR1A (0.38) | HRH4GRM5FFAR4HTR1A | |
| SCHEMBL25822642 | 0.83 | MAPT (0.46) | GRM5FFAR4 | |
| SCHEMBL25031334 | 0.82 | FFAR4 (0.47) | GRM5FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | HRH4 55/4885GRM5 1981/4885CNR1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.